Author

D. Ciznadija

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

I. Sloma· 2 shared A. Audia· 1 shared A. Bakayoko· 1 shared A. Wesa· 1 shared B. Vishwakarma· 1 shared B. Walling· 1 shared E. Gross· 1 shared F. Haderk· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

I. Sloma

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Pharmaco-Pheno-Multiomic Integration Reveals Biomarker Profiles and Therapeutic Response Prediction Models in Leukemia and Ovarian Cancer

G. Silberberg, B. Walling, A. Wesa, A. Audia, I. Sloma, Y. Zeng, G. Han, J. Tabg, P. Pammer, A. Bakayoko, X. Ren, D. Ciznadija, X. Ren, B. Vishwakarma, Y. Mosesson, , M. RItchie

This study integrates multi-omic and phenotypic data to predict therapeutic response in leukemia and ovarian cancer, identifying biomarker profiles and mechanisms of resistance.

bioRxiv · Jun 14, 2022Cancer Biology

A tyrosine kinase protein interaction map reveals targetable EGFR network oncogenesis in lung cancer

S. Kaushik, F. Haderk, X. Zhao, H.-M. Hu, K. N. Shah, G. M. Jang, V. Olivas, S. Nanjo, V. B. Masto, D. Ciznadija, I. Sloma, E. Gross, S. L. Weinrich, J. R. Johnson, T. G. Bivona, , S. Bandyopadhyay

The paper constructs a tyrosine kinase protein interaction map, revealing EGFR network oncogenesis in 19% of EGFR wild-type lung cancers, which is targetable with EGFR inhibitors.

bioRxiv · Jul 2, 2020 · PreprintCancer Biology